Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 5/20 | 0.36 |
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658209 | 0.78 | MEN1 (0.44) | RECQLSMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL225976 | 0.77 | SMN1; SMN2 (0.37) | RECQLSMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL711813 | 0.77 | MEN1 (0.52) | SMN1; SMN2NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL1457676 | 0.75 | MAPT (0.46) | RECQLSMN1; SMN2NPSR1MEN1KMT2A | |
| SCHEMBL14161834 | 0.75 | RECQL (0.38) | RECQLSMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL28366110 | 0.71 | RECQL (0.54) | RECQLSMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL7615873 | 0.67 | CYP2A6 (0.50) | SMN1; SMN2ALDH1A1HPGDRPS6KA5MEN1 | |
| SCHEMBL3868087 | 0.65 | ALDH1A1 (0.56) | SMN1; SMN2NPSR1ALDH1A1MEN1KMT2A | |
| SCHEMBL12020730 | 0.64 | RECQL (0.36) | RECQLSMN1; SMN2NPSR1ALDH1A1HPGD | |
| SCHEMBL10586653 | 0.63 | MTOR (0.71) | SMN1; SMN2ALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604205-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8604218-B2 | Cytoskeletal active rho kinase inhibitor compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130172324-A1 | METHOD FOR TREATING CARDIOVASCULAR DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130158014-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8410147-B2 | Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| CN-101583361-B | Cytoskeletal Active RHO Kinase Inhibitor Compounds, Compositions and Uses | INSPIRE PHARMACEUTICALS INC | 2013-01-23 | — | — | CN | disclosed |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2013-01-10 | — | — | US | disclosed |
| US-20130005756-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | NAVRATIL TOMAS (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299096-B2 | Method for treating pulmonary diseases using rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8207195-B2 | Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090325960-A1 | METHOD FOR TREATING INFLAMMATORY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325934-A1 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPATHIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325958-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325905-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009158587-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009155209-A1 | OPHTHALMIC FORMULATION OF RHO KINASE INHIBITOR COMPOUND | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| CN-101583361-A | Cytoskeletal Active RHO Kinase Inhibitor Compounds, Compositions and Uses | INSPIRE PHARMACEUTICALS INC (US) | 2009-11-18 | — | — | CN | disclosed |
| EP-2099457-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | Inspire Pharmaceuticals, Inc. (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | MERCK SHARP & DOHME LLC | 2008-09-04 | — | — | US | disclosed |
| WO-2008077057-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325960-A1 | METHOD FOR TREATING INFLAMMATORY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | RECQL 2479/4885SMN1; SMN2 4505/4885NPSR1 3399/4885 |
| US-20130012543-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | RECQL 808/4885SMN1; SMN2 1664/4885NPSR1 4132/4885 |
| US-20130158014-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOT2 | RECQL 2853/4885SMN1; SMN2 2528/4885NPSR1 4330/4885 |
| US-20130172324-A1 | METHOD FOR TREATING CARDIOVASCULAR DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | RECQL 3832/4885SMN1; SMN2 2433/4885NPSR1 758/4885 |
| US-20090325958-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, RHOA, ROCK2 | RECQL 1930/4885SMN1; SMN2 3093/4885NPSR1 2942/4885 |
| US-20090325905-A1 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOT2 | RECQL 2853/4885SMN1; SMN2 2528/4885NPSR1 4330/4885 |
| US-20080214614-A1 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | ROCK1, RHOA, ROCK2 | RECQL 808/4885SMN1; SMN2 1664/4885NPSR1 4132/4885 |
| US-20090325934-A1 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPATHIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, ROCK2, RHOA | RECQL 4394/4885SMN1; SMN2 74/4885NPSR1 649/4885 |
| US-20130005756-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, RHOA, ROCK2 | RECQL 1930/4885SMN1; SMN2 3093/4885NPSR1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.